<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02810743</url>
  </required_header>
  <id_info>
    <org_study_id>M16BRC</org_study_id>
    <nct_id>NCT02810743</nct_id>
  </id_info>
  <brief_title>Substantially Improving the Cure Rate of High-risk BRCA1-like Breast Cancer</brief_title>
  <acronym>Subito</acronym>
  <official_title>Substantially Improving the Cure Rate of High-risk BRCA1-like Breast Cancer Patients With Personalized Therapy (SUBITO) - an International Randomized Phase III Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Netherlands Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Netherlands Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Investigator-initiated, international, multicentre, randomized, open-label, (neo)adjuvant
      phase III study in target population (stage III, HER2-negative, BRCA1-like breast cancer
      patients) comparing optimized standard-dose chemotherapy with intensified, alkylating
      chemotherapy with stem cell rescue.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2016</start_date>
  <completion_date type="Anticipated">August 2029</completion_date>
  <primary_completion_date type="Anticipated">August 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>assessed up to 120 months</time_frame>
    <description>time from randomization to death from any cause.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Recurrence free interval</measure>
    <time_frame>assessed up to 120 months</time_frame>
    <description>time from randomization to local recurrence, second primary, distant recurrence or death, whichever comes first</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of toxicity, graded according to National Cancer Institute Common Toxicity Criteria (NCI-CTC) version 4.03</measure>
    <time_frame>up to 30 days after end of treatment</time_frame>
    <description>Incidence of toxicity, graded according to National Cancer Institute Common Toxicity Criteria (NCI-CTC) version 4.03</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cost-effectiveness measured by costs per quality-adjusted life years (QALYs)</measure>
    <time_frame>assessed up to 120 months</time_frame>
    <description>cost-effectiveness measured by costs per quality-adjusted life years (QALYs)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient reported outcomes</measure>
    <time_frame>assessed up to 24 months</time_frame>
    <description>Patient reported outcomes; including quality of life (QoL) determined by a comprehensive panel of QoL questionnaires</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cost-effectiveness measured by incremental cost-effectiveness ratio (ICER)</measure>
    <time_frame>assessed up to 120 months</time_frame>
    <description>cost-effectiveness measured by incremental cost-effectiveness ratio (ICER)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">174</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>ddAC-CP-Olaparib</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ddAC; doxorubicin 60 mg/m² as an i.v. bolus and cyclophosphamide 600 mg/m² as an i.v. bolus on day 1 every 2 weeks ddAC must be supported with prophylactic pegfilgrastim 6 mg s.c. given 24-48 hours after completion of administration of EVERY chemotherapy cycle
CP; carboplatin/paclitaxel (CP) consisting of carboplatin (AUC 6) on day 1 and paclitaxel (80 mg/m2) on day 1,8 and 15 of a 21 days cycle. In total 4 courses of CP will be administered.
Olaparib will be administered as monotherapy for one year at a dose of 300 mg BID, starting 3 weeks after adjuvant radiotherapy, or, if radiotherapy is not indicated, 3-5 weeks after the last CP cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ddAC-mini CTC</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ddAC; doxorubicin 60 mg/m² as an i.v. bolus and cyclophosphamide 600 mg/m² as an i.v. bolus on day 1 every 2 weeks ddAC must be supported with prophylactic pegfilgrastim 6 mg s.c. given 24-48 hours after completion of administration of EVERY chemotherapy cycle
intensified alkylating 'mini' CTC (2x) cyclophosphamide 3000 mg/m2 day 1 mesna 500 mg (push) + 2000 mg in 24 hours day 1 carboplatin (400 mg/m2; (or AUC=5 in patients with a calculated creatinine-clearance of &lt;100 ml/min)) days 1,2 thiotepa 250 mg/m2 day 2</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ddAC-CP-Olaparib</intervention_name>
    <description>ddAC-CP-Olaparib</description>
    <arm_group_label>ddAC-CP-Olaparib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ddAC-mini CTC</intervention_name>
    <description>ddAC - mini CTC</description>
    <arm_group_label>ddAC-mini CTC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women and men with stage III adenocarcinoma of the breast harboring signs of a breast
             cancer with features of homologous recombination deficiency (HRD)

          -  Age of 18-65 years

          -  The tumor must be HER2-negative

          -  Treatment must start within 8 weeks after the last surgical resection

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-1

        Exclusion Criteria:

          -  Previous radiation therapy

          -  Previous chemotherapy

          -  Any previous treatment with a PARP-inhibitor, including olaparib

          -  Pre-existing neuropathy from any cause in excess of Grade 1

          -  Chronic concomitant use of known strong or moderate CYP3A inducers
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sabine Linn, Prof. MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NKI-AvL</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sabine Linn, Prof. MD</last_name>
    <email>s.linn@nki.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sonja Vliek, MD</last_name>
    <email>s.vliek@nki.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Institut Paoli Calmettes</name>
      <address>
        <city>Marseille</city>
        <zip>13009</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>A Goncalves, MD</last_name>
    </contact>
    <investigator>
      <last_name>A Goncalves</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Tenon, University Marie-Curie</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>J-P Lotz, MD</last_name>
    </contact>
    <investigator>
      <last_name>J-P Lotz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Heinrich Heine University Düsseldorf, Women's Health Study Group</name>
      <address>
        <city>Dusseldorf</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>U Nitz, MD</last_name>
    </contact>
    <investigator>
      <last_name>U Nitz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical spectrum Twente</name>
      <address>
        <city>Enschede</city>
        <state>Overijssel</state>
        <zip>7500 KA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>M Wymenga, MD</last_name>
    </contact>
    <investigator>
      <last_name>M Wymenga, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Antoni van Leeuwenhoek</name>
      <address>
        <city>Amsterdam</city>
        <zip>1066 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sabine C Linn, MD</last_name>
      <phone>+3120512</phone>
      <phone_ext>2951</phone_ext>
      <email>s.linn@nki.nl</email>
    </contact>
    <contact_backup>
      <last_name>Sonja Vliek, MD</last_name>
      <email>s.vliek@nki.nl</email>
    </contact_backup>
    <investigator>
      <last_name>Sabine C Linn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AZVU</name>
      <address>
        <city>Amsterdam</city>
        <zip>1081 HV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>I Konings, MD</last_name>
      <email>i.konings@vumc.nl</email>
    </contact>
    <investigator>
      <last_name>I Konings, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Medical Center Groningen</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>C Schroder, MD</last_name>
    </contact>
    <investigator>
      <last_name>C Schroder, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>LUMC</name>
      <address>
        <city>Leiden</city>
        <zip>2333 ZA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>J R Kroep, MD</last_name>
      <email>j.r.kroep@lumc.nl</email>
    </contact>
    <investigator>
      <last_name>J R Kroep, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Maastricht University Medical Center</name>
      <address>
        <city>Maastricht</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>V Tjan-Heijnen, MD</last_name>
    </contact>
    <investigator>
      <last_name>V Tjan-Heijnen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Radboud UMC</name>
      <address>
        <city>NIjmegen</city>
        <zip>6225GA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>E Kuip, MD</last_name>
    </contact>
    <investigator>
      <last_name>E Kuip, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Erasmus Medical Center Cancer Institute</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015CE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>A Jager, MD</last_name>
    </contact>
    <investigator>
      <last_name>A Jager, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Medical Center Utrecht</name>
      <address>
        <city>Utrecht</city>
        <zip>3584CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>E van der Wall, MD</last_name>
    </contact>
    <investigator>
      <last_name>E van der Wall, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 16, 2016</study_first_submitted>
  <study_first_submitted_qc>June 20, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 23, 2016</study_first_posted>
  <last_update_submitted>September 13, 2017</last_update_submitted>
  <last_update_submitted_qc>September 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Olaparib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

